Evidence map›Paper›PMID 35618640›Full record

ArticleTransfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis2022

Human placenta-derived mesenchymal stromal cells transfusion in a critically Ill infant diagnosed with Coronavirus Disease 2019 (COVID-19): A case report.

Mehrdad Payandeh, Reza Habibi, Amir Hossein Norooznezhad, Zohreh Hoseinkhani, Feizollah Mansouri, Reza Yarani, Avnesh S Thakor, Mitra Bakhtiari, Farzaneh Esmailli, Kamran Mansouri

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Umbilical cord mesenchymal stromal cells-from bench to bedside.Frontiers in cell and developmental biology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mehrdad PayandehBone Marrow Transplantation Department, School of Medicine, Kermanshah, University of Medical Sciences, Kermanshah, Iran.
Reza HabibiDepartment of Pediatrics, School of Medicine, Kermanshah, University of Medical Sciences, Kermanshah, Iran.
Amir Hossein NorooznezhadMedical Biology Research Center, Health Technology Institute, Kermanshah, University of Medical Sciences, Kermanshah, Iran.
Zohreh HoseinkhaniMedical Biology Research Center, Health Technology Institute, Kermanshah, University of Medical Sciences, Kermanshah, Iran.
Feizollah MansouriEmam Reza Hospital, School of Medicine, Kermanshah, University of Medical Sciences, Kermanshah, Iran.
Reza YaraniTranslational Type 1 Diabetes Research, Department of Clinical, Research, Steno Diabetes Center Copenhagen, Gentofte, Denmark; Interventional Regenerative Medicine and Imaging Laboratory, Stanford University School of Medicine, Department of Radiology, Palo Alto, CA 94304, USA.
Avnesh S ThakorInterventional Regenerative Medicine and Imaging Laboratory, Stanford University School of Medicine, Department of Radiology, Palo Alto, CA 94304, USA.
Mitra BakhtiariMedical Biology Research Center, Health Technology Institute, Kermanshah, University of Medical Sciences, Kermanshah, Iran.
Farzaneh EsmailliMedical Technology Research Center Health Technology Institute, Kermanshah, University of Medical Sciences, Kermanshah, Iran.
Kamran MansouriMedical Biology Research Center, Health Technology Institute, Kermanshah, University of Medical Sciences, Kermanshah, Iran. Electronic address: kmansouri@kums.ac.ir.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19) is still an emergency in many countries. Herein, we report treatment with human placental-derived mesenchymal stromal cells transfusion (hPD-MSCT) in a critically ill infant diagnosed with COVID-19. A 28-day-old male infant with a history of pneumonia was referred to our center with decreased SpO

Indexed as

COVID-19Mesenchymal Stem CellsChildCritical IllnessFemaleHumansMalePlacentaPregnancySARS-CoV-2Cell therapyCOVID-19InflammationMesenchymal stromal cellsPlacenta

Identifiers

PMID35618640
PMCPMC9085352

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.